Clinical Study Number | 1297.2 |
---|---|
Study Indication | Arthritis, Rheumatoid |
Product | CYLTEZO ® |
Generic Name | Adalimumab-adbm |
Lab Code | BI 695501 |
Clinical Phase | III |
Study Title |
Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial |
Study Document | Lay summary 1297.2 english |
Clinical Study Number | 1297.12 |
---|---|
Study Indication | Psoriasis |
Product | CYLTEZO ® |
Generic Name | Adalimumab-adbm |
Lab Code | BI 695501 |
Clinical Phase | III |
Study Title |
Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial |
Study Document | Lay summary 1297.12 english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.